Opinion

Video

Introduction and HR+/HER2– eBC Overview

Author(s):

Kevin Kalinsky, MD, MS,Virginia Kaklamani, MD

Panelists discuss how HR+/HER2– early-stage breast cancer (eBC) is characterized by hormone receptor–positive, HER2-negative tumors, focusing on unmet patient needs, the goals of treatment in this setting, and the critical timing for discussing recurrence risk with patients.

Video content above is prompted by the following:

  • Please provide an overview of HR+/HER2– early-stage breast cancer (eBC). (Patient population, disease presentation, etc.)
    • What are unmet needs for these patients?
    • What are your goals in the eBC setting?
  • When do you talk to patients about the risk of recurrence?
Related Videos
Related Content